NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

argenx SE (ARGX) Stock Analysis

argenx SE (ARGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARGX

$1,033.15

−$20.31 (−1.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARGX with… →

ARGX Key Statistics

As of Sep 4, 2026
Trading
Open
$1,040.31
Previous Close
$1,053.46
Day's Range
1,031.19–1,048.44
52-Week Range
661.85–1,072.75
Volume
125.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.03
Valuation
Market Cap
$64.25B
P/E Ratio
40.15
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
26.28
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.27
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.09
EPS (ttm)Profit attributable to each share over the last twelve months.
25.73
Financials (FY)
Revenue (FY)
$4.15B+89.64%
Net Income (FY)
$1.29B+55.10%
Profit marginThe share of revenue left as profit after all costs and taxes.
32.27%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.19M
1-Year Return
+40.82%
Dividend and dates
Earnings Date
October 22, 2026
Avg Volume
324.94K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARGX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+22.86%
2025+36.74%
2024+61.66%
2023+0.42%
2022+8.18%
2021+19.08%
2020+83.21%
2019+67.09%
2018+52.15%
2017 (partial year)+174.52%

As of September 4, 2026.

ARGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.15B$1.29B31.1%
2024$2.19B$833.04M38.0%
2023$1.23B−$295.05M−24.1%
2022$410.75M−$709.59M−172.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.15B$3.70B$1.05B$1.29B31.1%
2024$2.19B$1.96B−$17.84M$833.04M38.0%
2023$1.23B$1.11B−$420.64M−$295.05M−24.1%
2022$410.75M$381.32M−$723.92M−$709.59M−172.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARGX Valuation vs Biotechnology Median

Median of 656 stocks
MetricARGXBiotechnology medianvs median
P/E40.1512.573.2x the median
P/S ratio12.0915.2621% below
Profit margin32.27%0.00%32.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values argenx SE (ARGX) at $64.25B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,863.

ARGX last closed at $1,033.15 on September 4, 2026. That is −$20.31 (−1.93%) against the previous close. Over the past 52 weeks the price has ranged from $661.85 to $1,072.75. The latest close sits 56.1% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.15B. That is +89.64% against the prior fiscal year, when revenue was $2.19B. The same year closed with net income of $1.29B. That is +55.10% against the prior fiscal year. The reported profit margin is 32.27%. That is 32.3 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 25.73.

Across the 4 fiscal years on file, revenue moves from $410.75M in 2022 to $4.15B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 40.15 times earnings. That is 3.2 times the Biotechnology median of 12.57. The forward P/E on file is 26.28. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.27. The price-to-sales ratio is 12.09. On price-to-sales that is 20.81% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +40.82%. Across 5 years the annualized return works out at +24.13%. Beta against the wider market is reported at −0.03. Annualized volatility over the trailing 9 years is 50.88%.

Growth & Income

The record shows no dividend for ARGX.

2026 is still running; the price is +22.86% year to date. The strongest complete calendar year on file is 2020 at +83.21%; the weakest is 2023 at +0.42%. Of the 8 complete calendar years on file, 8 finished higher.

Peer Comparison

argenx SE (ARGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
argenx SE ARGX $64.25B 40.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
Moderna, Inc. MRNA $58.11B —

The Biotechnology industry average P/E ratio is 12.6x. argenx SE trades at a P/E of 40.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B

 RPRX

Royalty Pharma plc

$36.96B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Visit website →